Nine weeks versus 1 year adjuvant trastuzumab in patients with early breast cancer: an observational study by the Turkish Oncology Group (TOG).
İçli F, Altundağ K, Akbulut H, Paydaş S, Başaran G, Saip P, Doğu GG, Eralp Y, Uslu R, Sevinç A, Onur H, Mandel NM, Sezgin C, Altınbaş M, Güler N, Işıkdoğan A, Gökmen E, Uygun K, Üstüner Z, Yaren A, Demirkan B, Coşkun U, Ata A, Özkan M, Arican A.
İçli F, et al. Among authors: basaran g.
Breast Cancer. 2015 Sep;22(5):480-5. doi: 10.1007/s12282-013-0506-y. Epub 2013 Dec 12.
Breast Cancer. 2015.
PMID: 24338610